Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD.

作者: Danuta Owczarek , Anetta Undas , Jonathan H. Foley , Michael E. Nesheim , Konrad Jabłonski

DOI: 10.1016/J.CROHNS.2011.06.005

关键词:

摘要: Abstract Background Thrombin activatable fibrinolysis inhibitor (TAFI) has been reported to be involved in the pathogenesis and progression of inflammatory bowel disease (IBD). Activated TAFI (TAFIa) attenuates by cleaving C-terminal lysine residues thus down-regulating plasminogen activation. To date, no reports on TAFIa IBD have published. Methods Plasma levels were measured using a functional assay 55 consecutive patients with ulcerative colitis (UC) 50 Crohn's (CD). Associations activity, hemostatic variables markers assessed. Results was higher CD than those UC. The activity correlated positively UC group, but not group. In patients, there positive correlations white blood cells, C-reactive protein fibrinogen an inverse correlation albumin. shown for protein, platelet count, while negative noted Conclusions This study is first show that increased compared its are associated both forms IBD. These findings fit hypothesis may marker active IBD, particular

参考文章(36)
Ioannis E. Koutroubakis, Aekaterini Sfiridaki, Georgia Tsiolakidou, Constantina Coucoutsi, Angeliki Theodoropoulou, Elias A. Kouroumalis, Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease European Journal of Gastroenterology & Hepatology. ,vol. 20, pp. 912- 916 ,(2008) , 10.1097/MEG.0B013E3282FAA759
Charles T. Esmon, The interactions between inflammation and coagulation British Journal of Haematology. ,vol. 131, pp. 417- 430 ,(2005) , 10.1111/J.1365-2141.2005.05753.X
Timothy Myles, Toshihiko Nishimura, Thomas H. Yun, Mariko Nagashima, John Morser, Andrew J. Patterson, Ronald G. Pearl, Lawrence L. K. Leung, Thrombin Activatable Fibrinolysis Inhibitor, a Potential Regulator of Vascular Inflammation * Journal of Biological Chemistry. ,vol. 278, pp. 51059- 51067 ,(2003) , 10.1074/JBC.M306977200
D. A. TREGOUET, R. SCHNABEL, M. C. ALESSI, T. GODEFROY, P. J. DECLERCK, V. NICAUD, T. MUNZEL, C. BICKEL, H. J. RUPPRECHT, E. LUBOS, T. ZELLER, I. JUHAN-VAGUE, S. BLANKENBERG, L. TIRET, P. E. MORANGE, , Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study Journal of Thrombosis and Haemostasis. ,vol. 7, pp. 49- 57 ,(2009) , 10.1111/J.1538-7836.2008.03221.X
S. Saibeni, B. Bottasso, L. Spina, M. Bajetta, S. Danese, A. Gasbarrini, R. de Franchis, M. Vecchi, Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. The American Journal of Gastroenterology. ,vol. 99, pp. 1966- 1970 ,(2004) , 10.1111/J.1572-0241.2004.30203.X
Alan C. Moss, Richard J. Farrell, Impotent immune system: an underlying problem in Crohn's disease. Gastroenterology. ,vol. 132, pp. 2609- 2611 ,(2007) , 10.1053/J.GASTRO.2007.04.050
R. BROUNS, E. HEYLEN, J. L. WILLEMSE, R. SHEORAJPANDAY, D. DE SURGELOOSE, R. VERKERK, P. P. DE DEYN, D. F. HENDRIKS, The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome Journal of Thrombosis and Haemostasis. ,vol. 8, pp. 75- 80 ,(2010) , 10.1111/J.1538-7836.2009.03663.X